LEADER 03237nam  2200733z- 450 
001 9910557608603321
005 20231214133343.0
035   $a(CKB)5400000000045316
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/79675
035   $a(EXLCZ)995400000000045316
100   $a20202203d2022      |y             0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aChronic HCV Infection: Clinical Advances and Eradication Perspectives
210   $aBasel$cMDPI - Multidisciplinary Digital Publishing Institute$d2022
215   $a1 electronic resource (104 p.)
311   $a3-0365-3361-3 
311   $a3-0365-3362-1 
330   $aHepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy.
517   $aChronic HCV Infection
606   $aMedicine$2bicssc
606   $aEpidemiology & medical statistics$2bicssc
610   $aHCV
610   $arheumatic
610   $ainterferon
610   $amortality
610   $ahepatitis C virus (HCV)
610   $aphylogeny
610   $aresistance-associated substitution (RAS)
610   $achronic hepatitis C
610   $avibration controlled transient elastography
610   $afibrosis
610   $asteatosis
610   $ahepatocellular carcinoma
610   $ahepatitis C
610   $agenotype 3
610   $aliver cirrhosis
610   $apangenotypic
610   $achildren
610   $aledipasvir/sofosbuvir
610   $areal-life
610   $asustained virological response
610   $aelimination
610   $amodel
610   $aCOVID-19
610   $aPWID
610   $ahomeless persons
610   $aHCV eradication
610   $adirect-acting antivirals
610   $aout-of-hospital
610   $aretention in care
615  7$aMedicine
615  7$aEpidemiology & medical statistics
700   $aLiberto$b Maria Carla$4edt$01302761
702   $aMarascio$b Nadia$4edt
702   $aLiberto$b Maria Carla$4oth
702   $aMarascio$b Nadia$4oth
906   $aBOOK
912   $a9910557608603321
996   $aChronic HCV Infection: Clinical Advances and Eradication Perspectives$93026524
997   $aUNINA